Shenzhen Hepalink Pharmaceutical Group - SHEZF Stock Price Target and Predictions

  • Consensus Rating: Sell
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00%
  • Number of Analysts: 1
  • Breakdown:
  • 1 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$0.72
+0 (0.00%)

This chart shows the closing price for SHEZF by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Shenzhen Hepalink Pharmaceutical Group Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for SHEZF and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for SHEZF

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 1 analysts offering 12 month price targets for Shenzhen Hepalink Pharmaceutical Group in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $0.72.

This chart shows the closing price for SHEZF for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Sell

The current consensus among 1 contributing investment analysts is to sell stock in Shenzhen Hepalink Pharmaceutical Group. This Sell consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 1 sell ratings
10/23/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 1 sell ratings
1/21/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 1 sell ratings
4/21/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 1 sell ratings
7/20/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 1 sell ratings
10/18/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 1 sell ratings
1/16/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 1 sell ratings
3/16/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 1 sell ratings
4/15/2024

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
10/5/2023The Goldman Sachs GroupDowngradeNeutral ➝ Sell
(Data available from 4/16/2019 forward)

News Sentiment Rating

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/18/2023
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/18/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/17/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/17/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/16/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/15/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/16/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/15/2024

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.

Shenzhen Hepalink Pharmaceutical Group

Shenzhen Hepalink Pharmaceutical Group Co., Ltd. engages in the manufacture and sale of pharmaceutical products in Hong Kong, the United States, Europe, Mainland China, and internationally. The company operates through four segments: Finished dose pharmaceutical products, Active Pharmaceutical Ingredients (API), Contract Development and Manufacturing Organization, and Others. Its pharmaceutical products consist of finished dose pharmaceutical products, which primarily include enoxaparin sodium injection; API products, including heparin sodium API and enoxaparin sodium API; and other products, such as pancreatin API. The company is also involved in the provision of research and development, manufacturing, quality management, and program management services; and development and manufacture of recombinant pharmaceutical products, critical non-viral vectors, intermediates for gene therapy, and naturally derived pharmaceutical products. In addition, it engages in property management, investment management and consulting, biopharmaceutical technology development and consulting, and equity and venture investment activities; research, development, production, and sell of biopharmaceuticals; production and sale of heparin sodium; provision of services on pharmaceutical related activities; and trading of medical and biopharmaceutical products. The company was formerly known as Shenzhen Hepalink Pharmaceutical Co.,Ltd. and changed its name to Shenzhen Hepalink Pharmaceutical Group Co., Ltd. in February 2017. Shenzhen Hepalink Pharmaceutical Group Co., Ltd. was founded in 1998 and is headquartered in Shenzhen, the People's Republic of China.
Read More

Today's Range

Now: $0.72
Low: $0.72
High: $0.72

50 Day Range

MA: $0.72
Low: $0.72
High: $0.72

52 Week Range

Now: $0.72
Low: $0.72
High: $0.72

Volume

N/A

Average Volume

N/A

Market Capitalization

N/A

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Shenzhen Hepalink Pharmaceutical Group?

The following Wall Street analysts have issued research reports on Shenzhen Hepalink Pharmaceutical Group in the last year: The Goldman Sachs Group, Inc..
View the latest analyst ratings for SHEZF.

What is the current price target for Shenzhen Hepalink Pharmaceutical Group?

0 Wall Street analysts have set twelve-month price targets for Shenzhen Hepalink Pharmaceutical Group in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Shenzhen Hepalink Pharmaceutical Group in the next year.
View the latest price targets for SHEZF.

What is the current consensus analyst rating for Shenzhen Hepalink Pharmaceutical Group?

Shenzhen Hepalink Pharmaceutical Group currently has 1 sell rating from Wall Street analysts. The stock has a consensus analyst rating of "Sell." A "sell" rating indicates that analysts believe SHEZF will underperform the market and that investors should sell shares of Shenzhen Hepalink Pharmaceutical Group.
View the latest ratings for SHEZF.

What other companies compete with Shenzhen Hepalink Pharmaceutical Group?

How do I contact Shenzhen Hepalink Pharmaceutical Group's investor relations team?

Shenzhen Hepalink Pharmaceutical Group's physical mailing address is No. 21 Langshan Road, Nanshan District, Shenzhen 518057, China. The company's listed phone number is 86-755-2698-0200. The official website for Shenzhen Hepalink Pharmaceutical Group is www.hepalink.com. Learn More about contacing Shenzhen Hepalink Pharmaceutical Group investor relations.